Cohance Lifesciences Limited has announced its intention to seek approval from the Central Government for the appointment of Mr. Umang Vohra as a Director and Chairman of the company. This strategic leadership change, effective from May 1, 2026, is subject to regulatory consent under Section 196 read with Part I of Schedule V of the Companies Act, 2013.

The company's Board of Directors had approved the appointment at its meeting held on April 27, 2026. Subsequently, the members of the company accorded their approval through a postal ballot conducted on June 13, 2026. The proposed tenure for Mr. Vohra extends until April 30, 2031, during which he will not be liable to retire by rotation.

Mr. Umang Vohra, identified as a Non-Resident with DIN 02296740, is also designated to take on the role of Group Chief Executive Officer effective May 20, 2026. The notice regarding this application was published in newspapers on June 26, 2026, in compliance with Section 201 of the Companies Act, 2013.

The company has ensured that the requisite information is available to shareholders and has been hosted on its official website. The move to appoint a new chairman and CEO comes as the company continues to operate under its former identity, Suven Pharmaceuticals Limited, during the transition period.

Berhyanda Limited, the promoter of Cohance Lifesciences , has declared that it has not created any encumbrance on the company's shares during the financial year 2025-26, other than those already disclosed. The declaration was submitted to the stock exchanges on April 7, 2026, under Regulation 31(4) of the SEBI (Substantial Acquisition of Shares & Takeover) Regulations, 2011.

The disclosure confirms that Berhyanda Limited, along with persons acting in concert (PACs) such as Jusmiral Holdings Limited, Berhyanda Midco Limited, and Jusmiral Midco Limited, has not directly or indirectly encumbered any shares beyond what was previously reported. The filing was addressed to the BSE and NSE for their information and records.

Key Details of the Disclosure

The following table outlines the entities involved in the declaration:

The letter was signed by Christodoulos Patsalides, Director of Berhyanda Limited. A copy of the declaration has also been forwarded to the Audit Committee of Cohance Lifesciences.